Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
COMMENTARY
Challenges in a Post-AG Era: Ensuring a Reliable Supply System
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an end to newly listed authorized generics (AGs) as a meaningful category. While generic manufacturers have welcomed the move as a…
To read the full story
Related Article
- Espha Snags Bilanoa AG in Final Pre-Rule Approval Window
February 17, 2026
- Will Unlisted AGs Rush for June Listing or Be Left on Ice?
January 23, 2026
- Chuikyo OKs 3.5% Minimum NHI Price Hike, Sets Grace Period for New AG Pricing
January 19, 2026
- Gist of FY2026 Drug Pricing Reform Outline
December 26, 2025
- Chuikyo OKs FY2026 Drug Pricing Reform Outline, Scraps “Spillovers” but Adds New Follow-Up Rules
December 26, 2025
- AG Price Parity Plan Stokes Industry Fears of Patient, Pharmacy Defections
December 12, 2025
- MHLW Proposes Pricing New AGs and Bio-AGs on Par with Originators
December 4, 2025
- Japan Moves to Advance “G1” Price Cuts by 5 Years under Proposed LLP Overhaul
November 20, 2025
COMMENTARY
- Japan Moves to Break Plasma Product Capacity Crunch with Factory Aid
October 6, 2026
- Survodutide Could Carve Out Role in MASH as Next-Gen Dual Agonist
September 28, 2026
- Regional Formularies Gain Ground, Raising Stakes for Drug Makers, Wholesalers
September 15, 2026
- As US Pushes Global Cost Rebalancing, Can Japan Answer with Drug Prices?
September 7, 2026
- Pharma Faces Wage Challenge in 5% Era as Industry Sustainability at Stake
September 3, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…